Atara Biotherapeutics (NASDAQ:ATRA) Given Neutral Rating at

HC Wainwright reaffirmed their neutral rating on shares of Atara Biotherapeutics (NASDAQ:ATRA – Free Report) in a research note issued to investors on Wednesday morning, Benzinga reports. HC Wainwright also issued estimates for Atara Biotherapeutics’ Q2 2024 earnings at $0.06 EPS, Q3 2024 earnings at ($0.28) EPS, Q4 2024 earnings at ($0.28) EPS, FY2024 earnings […]

Related Keywords

United States , Anhco Nguyen , Pascal Touchon , Harbor Capital Advisors Inc , Atara Biotherapeutics Inc , Vontobel Holding Ltd , Advisor Group , Josh Arnold Investment Consultant , Atara Biotherapeutics Company Profile , Delap Wealth Advisory , Free Report , Get Free Report , Wealth Advisory , Arnold Investment Consultant , Harbor Capital Advisors , Capital Advisors ,